Lexeo Therapeutics (LXEO) Other Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Other Accumulated Expenses data on file, last reported at $103000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 84.6% year-over-year to $103000.0; the trailing twelve-month figure through Mar 2026 stood at $103000.0 (down 84.6% YoY), and the FY2025 full-year result was $73000.0, down 86.61% from the prior year.
• Other Accumulated Expenses rose to $103000.0 in Q1 2026, from $73000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $669000.0 in Q1 2025 to a low of $73000.0 in Q4 2025.
• A 5-year average of $306250.0 and a median of $197500.0 in 2025 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 280.11% in 2025, while the deepest fall reached 86.61% in 2025.
• Tracing LXEO's Other Accumulated Expenses over 5 years: stood at $240000.0 in 2022, then soared by 130.83% to $554000.0 in 2023, then decreased by 1.62% to $545000.0 in 2024, then slumped by 86.61% to $73000.0 in 2025, then jumped by 41.1% to $103000.0 in 2026.
• Business Quant data shows LXEO's Other Accumulated Expenses at $103000.0 in Q1 2026, $73000.0 in Q4 2025, and $209000.0 in Q3 2025.